News
RMD
234.11
-0.69%
-1.63
INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?
NASDAQ · 11h ago
Weekly Report: what happened at RMD last week (1102-1106)?
Weekly Report · 1d ago
ResMed (RMD), Why Is It Getting Attention Now?
Simply Wall St · 2d ago
The Week That Was, The Week Ahead: Macro and Markets, November 8
TipRanks · 2d ago
Should You Buy ResMed Inc. (NYSE:RMD) For Its Upcoming Dividend?
Simply Wall St · 3d ago
Don't Lose Sleep Over GLP-1s. This Stock Is Still a Bargain.
Barron‘s · 4d ago
Dividend Champion, Contender, And Challenger Highlights: Week of November 8
Seeking Alpha · 4d ago
Zoetis Takes Over #296 Spot From ResMed
NASDAQ · 4d ago
ResMed Now #295 Largest Company, Surpassing Mettler-Toledo International
NASDAQ · 4d ago
Did Earnings Beat Just Shift ResMed's (RMD) Investment Narrative?
Simply Wall St · 5d ago
Don't Lose Sleep Over GLP-1s: Why ResMed Stock Is a Bargain
Barron‘s · 5d ago
Top 10 High Growth Dividend Stocks For November 2026
Seeking Alpha · 5d ago
ResMed Up Over 5%, on Pace for Largest Percent Increase Since April 2025 -- Data Talk
Dow Jones · 6d ago
ResMed: A Quality Compounder, But Not Yet A Bargain
Seeking Alpha · 11/03 16:16
Morgan Stanley Sticks to Their Hold Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
TipRanks · 11/03 07:56
*ResMed Downgraded to Hold from Buy by Canaccord Genuity
Dow Jones · 11/03 01:24
*ResMed Price Target Cut 11% to A$35.61/Share by Canaccord Genuity
Dow Jones · 11/03 01:24
ResMed's Rally Tempers Bull's Enthusiasm -- Market Talk
Dow Jones · 11/02 23:29
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Jarden
TipRanks · 11/02 22:36
*ResMed Cut to Accumulate From Buy by Morgans >RMD.AU
Dow Jones · 11/02 22:21
More
Webull provides a variety of real-time RMD stock news. You can receive the latest news about Resmed through multiple platforms. This information may help you make smarter investment decisions.
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.